Author:
Zinzani Pier Luigi,Dreyling Martin,Gradishar William,Andre Marc,Esteva Francisco J.,Boulos Suliman,González Barca Eva,Curigliano Giuseppe
Publisher
Springer Science and Business Media LLC
Reference123 articles.
1. Gulácsi L, Brodszky V, Baji P, Rencz F, Péntek M. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017;34(5):1128–44. https://doi.org/10.1007/s12325-017-0522-y .
2. Lee S-M, Jung J-H, Suh D, Jung Y-S, Yoo S-L, Kim D-W, et al. Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European countries. BioDrugs. 2019;33(4):423–36. https://doi.org/10.1007/s40259-019-00359-0 .
3. European Medicines Agency. Inflectra: Summary of Medicinal Product Characteristics. 2019. https://www.ema.europa.eu/en/documents/product-information/inflectra-epar-product-information_en.pdf . Accessed 02 Sep 2019.
4. United States Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. https://www.fda.gov/media/82647/download . Accessed 02 Sep 2019.
5. British National Formulary. Rituximab medicinal forms. https://bnf.nice.org.uk/medicinal-forms/rituximab.html . Accessed 02 Sep 2019.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献